![Quantitative SERS Detection of Uric Acid via Formation of Precise Plasmonic Nanojunctions within Aggregates of Gold Nanoparticles and Cucurbit[n]uril](/_next/image?url=https%3A%2F%2Fcloudfront.jove.com%2FCDNSource%2Fteasers%2F61682.jpg&w=3840&q=50)
Single-atom nanozyme-based wireless microfluidic sensing platform for noninvasive hyperuricemia diagnosis
Jiaying Zhao1, Jia Zheng1, Kezheng Wei1
1Department of Endocrinology, Metabolic and Chronic Disease Science Innovation Center, Translational Research of Diabetes Key Laboratory of Chongqing, The Second Affiliated Hospital of Army Medical University, Chongqing, 400037, China.
Biosensors & Bioelectronics
|August 9, 2026
Summary
A new portable sensor uses single-atom catalysts to detect elevated uric acid (UA) levels in blood and saliva. This non-invasive device offers early hyperuricemia diagnosis and monitoring for better patient outcomes.
Area of Science:
- Electrochemistry
- Materials Science
- Biomedical Engineering
Background:
- Hyperuricemia, marked by high serum uric acid (UA), is linked to gout, kidney, and cardiovascular issues.
- Early, non-invasive monitoring of UA is vital for preventing disease progression and complications.
Purpose of the Study:
- To develop a portable, wireless electrochemical sensing platform for non-invasive uric acid detection.
- To create a sensitive, selective, and reproducible method for early hyperuricemia diagnosis.
Main Methods:
- Fabrication of a sensing platform using single-atom catalysts (SA-Pt/rGO/MOF) via photochemical deposition.
- Integration of a hydrophilic microfluidic device for enhanced biofluid collection and analysis.
- Quantitative analysis of UA in serum and saliva from hyperuricemia patients and healthy volunteers.
Main Results:
- The sensing platform exhibited high electrocatalytic activity for UA oxidation.
- Achieved a broad linear detection range (1-1000 µM) with a low detection limit (1.12 µM).
- Demonstrated excellent selectivity, reproducibility, and promising clinical utility in patient samples.
Conclusions:
- The developed platform offers a feasible strategy for next-generation non-invasive point-of-care testing (POCT).
- Single-atom catalysts show potential for ultrasensitive biomarker detection in clinical diagnostics.
